Molecular Profile of Advanced Radioiodine-refractory Thyroid Cancer and Response to Lenvatinib Treatment
The RAIR-TC molecular profile is heterogeneous with TERT being the most frequent mutation. Cases negative for all mutations and cases presenting the coexistence of TERT + driver mutation had a worse response to lenvatinib. Conversely, the presence of 1 driver mutation correlated with a better response to lenvatinib.
Authors
- Elisa Minaldi (ORCID: https://orcid.org/0000-0002-4144-4906)
- Antonio Matrone (ORCID: https://orcid.org/0000-0003-4263-4717)
- Raffaele Ciampi (ORCID: https://orcid.org/0000-0001-6345-9343)
- Carla Gambale (ORCID: https://orcid.org/0000-0002-0996-8486)
- Roberta Casalini (ORCID: https://orcid.org/0009-0001-6017-5166)
- Rossella Elisei (ORCID: https://orcid.org/0000-0002-5333-9257)
- Laura Agate
- Loredana Lorusso (ORCID: https://orcid.org/0000-0001-8773-3642)
- Teresa Ramone
- Cristina Romei
- Alessandro Prete
- Paolo Piaggi
- Liborio Torregrossa
Institutions
- University of Pisa (IT)
Publication Details
- Journal
- The Journal of Clinical Endocrinology & Metabolism
- Published
- 2026-03-26
- DOI
- https://doi.org/10.1210/clinem/dgag074
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00